EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation


Clinical and Translational Science 7(1): 82-86
Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation
Translational stories range from straightforward to complex. In this commentary, the story of the rapid and successful translation of rituximab therapy for the treatment of non-Hodgkin's lymphoma (NHL) is examined. Development of this monoclonal antibody therapy began in the late 1980s. In 1994, rituximab received its first approval for the treatment of NHL by the United States Food and Drug Administration (FDA). Rituximab has since been approved for additional indications and has transformed medical practice. However, the social and political implications of these rapid successes are only beginning to become clear. In this commentary, key events in the rapid translation of rituximab from the bench to bedside are highlighted and placed into this historical framework. To accomplish this, the story of rituximab is divided into the following six topics, which we believe to be widely applicable to case studies of translation: (1) underlying disease, (2) key basic science, (3) key clinical studies in translation, (4) FDA approval process, (5) changes to medical practice, and (6) the social and political influences on translation.

(PDF same-day service: $19.90)

Accession: 055589976

PMID: 24528902

DOI: 10.1111/cts.12111



Related references

Monoclonal antibody therapy of non-Hodgkin's lymphoma: the Rituximab story. Journal of the Medical Association of Georgia 92(1): 39-46, 2003

Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. Journal of Clinical Oncology 32(36): 4127-4133, 2015

BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma. Leukemia & Lymphoma 54(9): 2081-2082, 2014

Safety and efficacy of non-initial rapid infusion of rituximab plus chemotherapy in Chinese patients with CD20+ non-Hodgkin's lymphoma. Expert Opinion on Drug Safety 14(1): 21-29, 2015

A prospective study of left ventricle function after treatment with rapid-infusion rituximab in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma 50(10): 1642-1646, 2010

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 111(1): 109-111, 2007

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 111(1): 109-111, 2008

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 101(2): 420-424, 2003

Acute adverse reactions of rapid Rituximab infusion among adult patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Jbi Library of Systematic Reviews 9(1): 1-30, 2011

Rapid-progressive decrease of cognitive and physical functions in a B-cell non-Hodgkin's lymphoma patient treated with rituximab/bendamustine. Deutsche Medizinische Wochenschrift 138(25-26): 1355-1359, 2013